Jia Zhong
Education
Sc.D., environmental health, Harvard T.H. Chan School of Public Health; M.S., biochemistry and molecular biology, Chinese Academy of Sciences; B.S., applied molecular biology, Zhejiang University, China
Summary of Experience
Dr. Zhong is an epidemiologist who specializes in clinical health economics and outcomes research (HEOR), clinical trials, and large-scale epidemiological studies. She has more than 15 years’ research experience in disease areas such as hematology, pulmonary diseases, diabetes, cardiovascular diseases, oncology, rare diseases, and immunology. Dr. Zhong’s expertise includes comparative efficacy and safety, individualized medicine, predictive modeling, and longitudinal analysis. Her recent work includes leading large-scale prospective cohort studies, evaluating the comparative efficacy of immuno-oncology treatments for regulatory submissions, quantifying direct and indirect resource utilization and costs, and evaluating real-world effectiveness using patient reported outcomes (PROs). Her research has been published in Nature Immunology, Immunity, Proceedings of the National Academy of Sciences, Circulation, Circulation Research, Hypertension, and the International Journal of Epidemiology, among other publications. Prior to joining Analysis Group, Dr. Zhong was a research scientist at the Columbia University Mailman School of Public Health, where she developed data-based therapeutic target identification frameworks.
-
Real-world Data for Healthcare Research in China: Call for Actions
Value in Health Regional Issues, Volume 27, 2022
2022 -
Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
Journal of Managed Care & Specialty Pharmacy, 2020
2020Zhou ZY, Raimundo K, Patel A, Han S, Ji Y, Fang H, Zhong J, Betts K, Mahajerin A
-
An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies
Haemophilia, 27 November 2020
2020Song X, Zhong J, Xue F, Chen L, Li H, Yuan D, Xie J, Shi J, Zhang L, Wu E, Yang R
-
Real‐world analysis of haemophilia patients in China: A single centre’s experience
Haemophilia, 20 May 2020
2020Song X, Liu W, Xue F, Zhong J, Yang Y, Liu Y, Xie, J, Wu E, Zhang L, Shi J, Yang R
-
Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real-World Population
JBMR Plus, 2020
2020Kilpatrick RD, Chiuve SE, Leslie WD, Wegrzyn LR, Gao W, Yang H, Soliman AM, Snabes MC, Koenigsberg S, Zhong J, Xiang C, Watts NB
-
The cost-effectiveness of low-dose budesonide as a Step 2 treatment for pediatric asthma in China
Journal of Comparative Effectiveness Research, 2020
2020Wang X, Fang H, Shen K, Liu T, Xie J, Liu Y, Zhong J, Wu E, Zhou W, Wu B
-
Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China
Journal of Medical Economics, 2020
2020Wang X, Fang H, Shen K, Liu T, Xie J, Liu Y, Wu P, Chen Y, Zhong J, Wu E, Zhou W, Wu B
-
May 15, 2022
-
June 19, 2022
-
November 6, 2022
-
November 12, 2023
-
June 27, 2023
-
November 1, 2022
-
May 12, 2022
-
March 1, 2022
-
February 11, 2022
-
February 9, 2021